The intrathecally administered kappa-2 opioid agonist gr89696 and interleukin-10 attenuate bone cancer-induced pain through synergistic interaction

Anesthesia and Analgesia

Volumn 113, Issue 4, 2011, Pages 934-940

  Kim, Woong Mo ^a   Jeong, Cheol Won ^a   Lee, Seong Heon ^a   Kim, Yeo Ok ^a   Cui, Jin Hua ^a   Yoon, Myung Ha ^a  

^a Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(3,4 DICHLOROPHENYL)ACETYL] 3 (1 PYRROLIDINYLMETHYL) 1 PIPERAZINECARBOXYLIC ACID METHYL ESTER; ANALGESIC AGENT; INTERLEUKIN 10;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE CANCER; CANCER PAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT;

EID: 80053323645     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e318227824e     Document Type: Article

References (39)

1. Burton AW, Fanciullo GJ, Beasley RD, Fisch MJ. Chronic pain in the cancer survivor: a new frontier. Pain Med 2007;8:189-98
2. Halvorsan KG, Sullivan LJ, Mantyh PW. Bone pain. In: Fisch MJ, Burton AW, eds. Cancer Pain Management. 1st ed. New York: McGraw-Hill, 2007:75-86
3. Fitzgibbon DR. Cancer pain: principles of management and pharmacotherapy. In: Fishman SM, Ballantyne JC, Rathmell JP, eds. Bonicás Management of Pain. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2009:583-603
4. Luger NM, Sabino MA, Schwei MJ, Mach DB, Pomonis JD, Keyser CP, Rathbun M, Clohisy DR, Honore P, Yaksh TL, Mantyh PW. Efficacy of systemic morphine suggests a fundamental difference in the mechanisms that generate bone cancer vs inflammatory pain. Pain 2002;99:397-406 (Pubitemid 35284270)
5. Yamamoto J, Kawamata T, Niiyama Y, Omote K, Namiki A. Down-regulation of mu opioid receptor expression within distinct subpopulations of dorsal root ganglion neurons in a murine model of bone cancer pain. Neuroscience 2008;151: 843-53
6. King T, Vardanyan A, Majuta L, Melemedjian O, Nagle R, Cress AE, Vanderah TW, Lai J, Porreca F. Morphine treatment accelerates sarcoma-induced bone pain, bone loss, and spontaneous fracture in a murine model of bone cancer. Pain 2007;132:154-68 (Pubitemid 47494569)
7. Rivière PJM. Opioids, kappa receptors and visceral pain. In Schmidt RF, Willis WD, eds. Encyclopedia of Pain. 1st ed. New York: Springer, 2007: 1606-9.
8. Stein C, Millan MJ, Yassouridis A, Herz A. Antinociceptive effects of mu-and kappa-agonists in inflammation are enhanced by a peripheral opioid receptor-specific mechanism. Eur J Pharmacol 1988;155:255-64
9. Keita H, Kayser V, Guilbaud G. Antinociceptive effect of a kappa-opioid receptor agonist that minimally crosses the blood-brain barrier (ICI 204448) in a rat model of mononeuropathy. Eur J Pharmacol 1995;277:275-80
10. Burton MB, Gebhart GF. Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther 1998;285:707-15 (Pubitemid 28237452)
11. Baamonde A, Lastra A, Juarez L, Garcia V, Hidalgo A, Menendez L. Effects of the local administration of selective mu-, delta-and kappa-opioid receptor agonists on osteosarcoma-induced hyperalgesia. Naunyn Schmiedebergs Arch Pharmacol 2005;372:213-9 (Pubitemid 41668750)
12. Ho J, Mannes AJ, Dubner R, Caudle RM. Putative kappa-2 opioid agonists are antihyperalgesic in a rat model of inflammation. J Pharmacol Exp Ther 1997;281:136-41 (Pubitemid 27203061)
13. Schmauss C, Yaksh TL. In vivo studies on spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a differential association of mu, delta and kappa receptors with visceral chemical and cutaneous thermal stimuli in the rat. J Pharmacol Exp Ther 1984;228:1-12 (Pubitemid 14223374)
14. Geis C, Graulich M, Wissmann A, Hagenacker T, Thomale J, Sommer C, Schafers M. Evoked pain behavior and spinal glia activation is dependent on tumor necrosis factor receptor 1 and 2 in a mouse model of bone cancer pain. Neuroscience 2010;169:463-74
15. Zhang RX, Liu B, Li A, Wang L, Ren K, Qiao JT, Berman BM, Lao L. Interleukin 1beta facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phosphorylation. Neuroscience 2008;154:1533-8
16. Wagner R, Janjigian M, Myers RR. Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNFalpha expression. Pain 1998;74:35-42 (Pubitemid 28097727)
17. Karam MC, Hamdan HG, Abi Chedid NA, Bodman-Smith KB, Baroody GM. Interleukin-10 reduces hyperalgesia and the level of interleukin-1beta in BALB/c mice infected with Leishmania major with no major effect on the level of interleukin-6. J Neuroimmunol 2007;183:43-9 (Pubitemid 46204905)
18. Beyreuther BK, Callizot N, Brot MD, Feldman R, Bain SC, Stohr T. Antinociceptive efficacy of lacosamide in rat models for tumor-and chemotherapy-induced cancer pain. Eur J Pharmacol 2007;565:98-104 (Pubitemid 46782774)
19. Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976;17:1031-6 (Pubitemid 8063691)
20. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994;53:55-63 (Pubitemid 24238751)
21. Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001;298:865-72 (Pubitemid 32761897)
22. Tallarida RJ. Drug Synergism and Dose-Effect Data Analysis. 1st ed. New York: Chapman & Hall/CRC, 2000
23. Medhurst SJ, Walker K, Bowes M, Kidd BL, Glatt M, Muller M, Hattenberger M, Vaxelaire J, ÓReilly T, Wotherspoon G, Winter J, Green J, Urban L. A rat model of bone cancer pain. Pain 2002;96:129-40
24. Nagae M, Hiraga T, Yoneda T. Acidic microenvironment created by osteoclasts causes bone pain associated with tumor colonization. J Bone Miner Metab 2007;25:99-104 (Pubitemid 46328665)
25. Rothman RB, Bykov V, de Costa BR, Jacobson AE, Rice KC, Brady LS. Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain. Peptides 1990;11:311-31 (Pubitemid 20144902)
26. Caudle RM, Chavkin C, Dubner R. Kappa 2 opioid receptors inhibit NMDA receptor-mediated synaptic currents in guinea pig CA3 pyramidal cells. J Neurosci 1994;14:5580-9
27. Caudle RM, Mannes AJ, Iadarola MJ. GR89,696 is a kappa-2 opioid receptor agonist and a kappa-1 opioid receptor antagonist in the guinea pig hippocampus. J Pharmacol Exp Ther 1997;283:1342-9 (Pubitemid 28016509)
28. Butelman ER, Ko MC, Traynor JR, Vivian JA, Kreek MJ, Woods JH. GR89,696: a potent kappa-opioid agonist with subtype selectivity in rhesus monkeys. J Pharmacol Exp Ther 2001; 298:1049-59 (Pubitemid 32761921)
29. Rusovici DE, Negus SS, Mello NK, Bidlack JM. Kappa-opioid receptors are differentially labeled by arylacetamides and benzomorphans. Eur J Pharmacol 2004;485:119-25 (Pubitemid 38134405)
30. Caudle RM, Finegold AA, Mannes AJ, Tobias MD, Kenshalo DR Jr, Iadarola MJ. Spinal kappa1 and kappa2 opioid binding sites in rats, guinea pigs, monkeys and humans. Neuroreport 1998;9:2523-5 (Pubitemid 28387142)
31. Wacnik PW, Eikmeier LJ, Simone DA, Wilcox GL, Beitz AJ. Nociceptive characteristics of tumor necrosis factor-alpha in naive and tumor-bearing mice. Neuroscience 2005;132:479-91 (Pubitemid 40417919)
32. Baamonde A, Curto-Reyes V, Juarez L, Meana A, Hidalgo A, Menendez L. Antihyperalgesic effects induced by the IL-1 receptor antagonist anakinra and increased IL-1beta levels in inflamed and osteosarcoma-bearing mice. Life Sci 2007;81: 673-82 (Pubitemid 47268018)
33. Liu S, Yang J, Wang L, Jiang M, Qiu Q, Ma Z, Liu L, Li C, Ren C, Zhou J, Li W. Tibia tumor-induced cancer pain involves spinal p38 mitogen-activated protein kinase activation via TLR4-dependent mechanisms. Brain Res 2010;1346:213-23
34. Moore KW, de Waal Malefyt R, Coffman RL, ÓGarra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765 (Pubitemid 32368050)
35. Laughlin TM, Bethea JR, Yezierski RP, Wilcox GL. Cytokine involvement in dynorphin-induced allodynia. Pain 2000; 84:159-67 (Pubitemid 30074217)
36. Chacur M, Milligan ED, Sloan EM, Wieseler-Frank J, Barrientos RM, Martin D, Poole S, Lomonte B, Gutierrez JM, Maier SF, Cury Y, Watkins LR. Snake venom phospholipase A2s (Asp49 and Lys49) induce mechanical allodynia upon peri-sciatic administration: involvement of spinal cord glia, proinflammatory cytokines and nitric oxide. Pain 2004;108:180-91 (Pubitemid 38251688)
37. Milligan ED, Langer SJ, Sloane EM, He L, Wieseler-Frank J, ÓConnor K, Martin D, Forsayeth JR, Maier SF, Johnson K, Chavez RA, Leinwand LA, Watkins LR. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci 2005;21:2136-48 (Pubitemid 40695238)
38. Garrison CJ, Dougherty PM, Carlton SM. GFAP expression in lumbar spinal cord of naive and neuropathic rats treated with MK-801. Exp Neurol 1994;129:237-43 (Pubitemid 24365942)
39. Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factoralpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci 2008;28:5189-94